Evidence map›Paper›PMID 25719413›Full record

ArticleCancer biology & therapy2015

Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer.

Giandomenico Roviello, Edoardo Francini, Armando Perrella, Letizia Laera, Maria Antonietta Mazzei, Susanna Guerrini, Franco Roviello, Daniele Marrelli, Roberto Petrioli

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in Cancer biology & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Giandomenico Rovielloa Medical Oncology Unit; University of Siena ; Siena , Italy.
Edoardo Francini
Armando Perrella
Letizia Laera
Maria Antonietta Mazzei
Susanna Guerrini
Franco Roviello
Daniele Marrelli
Roberto Petrioli
University of Siena · ITCenter for Special Minimally Invasive and Robotic Surgery · USPoliclinico Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bevacizumab and Tamoxifen are valid therapeutic options for metastatic breast cancer (mBC) patients. In this report, we describe a 47 year old woman with mBC successfully treated with a maintenance therapy with Bevacizumab+Tamoxifen. A maintenance approach using 2 different drugs with different targets and mechanism of action, such as anti-angiogenic and anti-hormonal treatment is particularly intriguing because they affect different pathways involved in mBC progression. Further studies including a large number of patients are needed, in order to select women who could benefit from this maintenance approach.

Indexed as

Angiogenesis InhibitorsAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBreast NeoplasmsFemaleHumansMiddle AgedTamoxifenAngiogenesis InhibitorsAntineoplastic Agents, HormonalBevacizumabTamoxifenbevacizumabmaintenance therapymetastatic breast cancertamoxifen

Identifiers

PMID25719413
PMCPMC4622062
OpenAlexW1530841853

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.